HR 1.19, 95% CI 0.91.58), but not for the other DPP-4 inhibitors as in the TECOS study for sitagliptin (HR 1.00, 95% CI 0.831.20) or the CARMELINA study for linagliptin (HR 0.90, 95% CI 0.741.08) (57, 62, 64, 65, 68)
The Bottom Line Success on GLP-1 medications isn't just about taking your weekly injectionit's about pairing that medication with a strategic nutrition approach that preserves muscle, minimizes side effects, and sets you up for long-term sustainable weight loss
On the contrary, studies in animal models of IBD suggest that the use of DPP-IV inhibitors decreases disease activity
While tracking weight can motivate, the main goal is to understand how symptoms such as nausea, fatigue, and appetite suppression change throughout the week
PlexusDx's tiered commitment options let you progress at a pace your body tolerates
Though it tracks basic protein intake, its not linked to any broader food database